NWBONorthwest Biotherapeutics, Inc.

About Northwest Biotherapeutics, Inc. (NWBO)

Northwest Biotherapeutics, Inc. (NWBO) is a Biotechnology company headquartered in Bethesda, MD, United States whose shares trade over-the-counter on the OTCQB tier.

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program involves DCVax®-L treatment for glioblastoma (GBM).

Products and services

The Company was organized to discover and develop innovative immunotherapies for cancer. NWBO has developed DCVax® platform technologies for both operable and inoperable solid tumor cancers.

NWBO key facts

Ticker symbol

NWBO

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Bethesda, MD, United States

Country of incorporation

US

Year of incorporation

1998

Employees

25

Estimated market cap

$298.57M (as of Apr 15, 2025)

Shares outstanding

1,399,231,533

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Northwest Biotherapeutics, Inc. leadership

• Linda Francis Powers — CEO, President, Chief Accounting Officer
• Dr. Alton Boynton — Chief Scientific Officer
• Marnix L Bosch — CTO
• Leslie Jay Goldman — General Counsel
• Bruce Poignant — Consultant
• Tamara Kondic — Consultant

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with N